Articles with public access mandates - Daniel SargentLearn more
Not available anywhere: 13
Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III …
SR Alberts, DJ Sargent, TC Smyrk, AF Shields, E Chan, RM Goldberg, ...
Journal of Clinical Oncology 28 (18_suppl), CRA3507-CRA3507, 2010
Mandates: US National Institutes of Health
Alternate endpoints for screening phase II studies
N Dhani, D Tu, DJ Sargent, L Seymour, MJ Moore
Clinical Cancer Research 15 (6), 1873-1882, 2009
Mandates: US National Institutes of Health
Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147.
RM Goldberg, DJ Sargent, SN Thibodeau, MR Mahoney, AF Shields, ...
Journal of Clinical Oncology 28 (15_suppl), 3508-3508, 2010
Mandates: US National Institutes of Health
Adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup phase III trial N0147.
J Huang, DJ Sargent, MR Mahoney, SN Thibodeau, TC Smyrk, ...
Journal of Clinical Oncology 29 (4_suppl), 363-363, 2011
Mandates: US National Institutes of Health
New insights into the evaluation of randomized controlled trials for rare diseases over a long‐term research horizon: a simulation study
MA Bayar, G Le Teuff, S Michiels, DJ Sargent, MC Le Deley
Statistics in medicine 35 (19), 3245-3258, 2016
Mandates: US National Institutes of Health
A hierarchical Bayesian design for randomized phase II clinical trials with multiple groups
J Yin, R Qin, DJ Sargent, C Erlichman, Q Shi
Journal of Biopharmaceutical Statistics 28 (3), 451-462, 2018
Mandates: US National Institutes of Health
Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from …
SR Alberts, SN Thibodeau, DJ Sargent, MR Mahoney, F Sinicrope, ...
Journal of Clinical Oncology 29 (15_suppl), 3607-3607, 2011
Mandates: US National Institutes of Health
Pilot experience with adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup N0147.
J Huang, DJ Sargent, MR Mahoney, AF Shields, E Chan, RM Goldberg, ...
Journal of Clinical Oncology 29 (15_suppl), 3522-3522, 2011
Mandates: US National Institutes of Health
Clinical validation of biomarkers in cancer
SJ Mandrekar, DJ Sargent
Molecular Diagnostics, 227-250, 2019
Mandates: US National Institutes of Health
Reply to SA Kesikli et al
J Franko, D Sargent, A Grothey
Journal of Clinical Oncology 30 (18), 2288-2289, 2012
Mandates: US National Institutes of Health
Reply to ID Nagtegaal et al
LL Gunderson, JM Jessup, DJ Sargent, FL Greene, A Stewart, ...
Journal of Clinical Oncology 28 (23), e399-e400, 2010
Mandates: US National Institutes of Health
Reply to MA Rosen et al
SL Hillman, DJ Sargent
Journal of Clinical Oncology 28 (10), e161-e161, 2010
Mandates: US National Institutes of Health
Reply to P. Prassopoulos et al
SL Hillman, DJ Sargent
Journal of Clinical Oncology 28 (5), e82-e82, 2010
Mandates: US National Institutes of Health
Available somewhere: 180
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
F Pagès, B Mlecnik, F Marliot, G Bindea, FS Ou, C Bifulco, A Lugli, ...
The Lancet 391 (10135), 2128-2139, 2018
Mandates: US National Institutes of Health, National Institute of Health and Medical …
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer
DJ Sargent, S Marsoni, G Monges, SN Thibodeau, R Labianca, ...
Journal of clinical oncology 28 (20), 3219-3226, 2010
Mandates: US National Institutes of Health
Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy
S Kopetz, GJ Chang, MJ Overman, C Eng, DJ Sargent, DW Larson, ...
Journal of clinical oncology 27 (22), 3677-3683, 2009
Mandates: US National Institutes of Health
Effect of laparoscopic-assisted resection vs open resection of stage II or III rectal cancer on pathologic outcomes: the ACOSOG Z6051 randomized clinical trial
J Fleshman, M Branda, DJ Sargent, AM Boller, V George, M Abbas, ...
Jama 314 (13), 1346-1355, 2015
Mandates: US National Institutes of Health
Duration of adjuvant chemotherapy for stage III colon cancer
A Grothey, AF Sobrero, AF Shields, T Yoshino, J Paul, J Taieb, ...
New England Journal of Medicine 378 (13), 1177-1188, 2018
Mandates: US National Institutes of Health, Cancer Research UK, UK Medical Research …
Benefit of adjuvant chemotherapy for resectable gastric cancer a meta-analysis
X Paoletti, K Oba, T Burzykowski, S Michiels, Y Ohashi, JP Pignon, ...
AMER MEDICAL ASSOC, 2010
Mandates: Cancer Research UK
Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials
D Sargent, A Sobrero, A Grothey, MJ O'Connell, M Buyse, T Andre, ...
Journal of Clinical Oncology 27 (6), 872-877, 2009
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program